Santhera Report issue

For profit Phase 1 Phase 2 Phase 4
Founded: Liestal Switzerland (2004)
Status: Acquired by Biovail (2009) → now Bausch Health Companies (2010)

Organization Overview

First Clinical Trial
2005
NCT00654784
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Santhera Pharmaceuticals

Active Ingredients

Drugs in Phase 4 Trials (1)

idebenone (18 trials)

Drugs in Phase 2 Trials (3)

Key: Santhera (2) Acquired (1)

fipamezole (2 trials)

pol6014 (1 trial)

vamorolone (2 trials)

Drugs in Phase 1 Trials (2)

midazolam (versed) (1 trial)

omigapil (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acidosis (Phase 2)

Acidosis, Lactic (Phase 2)

Ataxia (Phase 3)

Atrophy (Phase 2)

Brain Diseases (Phase 2)

Cerebellar Ataxia (Phase 3)

Cystic Fibrosis (Phase 2)

Fibrosis (Phase 2)

Friedreich Ataxia (Phase 3)

Hypotension (Phase 2)

Hypotension, Orthostatic (Phase 2)

MELAS Syndrome (Phase 2)

Multiple System Atrophy (Phase 2)

Muscular Dystrophies (Phase 3)

Muscular Dystrophy, Duchenne (Phase 3)

Optic Atrophy, Hereditary, Leber (Phase 4)

Optic Nerve Diseases (Phase 4)

Parkinson Disease (Phase 2)

Peripheral Nervous System Diseases (Phase 2)

Shy-Drager Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 24
  • # of Trial APIs: 6